AI Verdict
MD has stronger fundamentals based on our AI analysis.
MDCXW vs MD Fundamental Comparison
| Metric | MDCXW | MD |
|---|---|---|
| Revenue | $-197,382.0 | $1.9B |
| Net Income | $-47.3M | $165.4M |
| Net Margin | 23,954.3% | 8.6% |
| ROE | N/A | 19.1% |
| ROA | -469.9% | 7.4% |
| Current Ratio | 1.00x | 1.66x |
| Debt/Equity | N/A | 0.69x |
| EPS | $-2.74 | $1.94 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
MDCXW vs MD: Frequently Asked Questions
Is MDCXW or MD a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), MD has stronger fundamentals. MDCXW is rated STRONG SELL (95% confidence) while MD is rated HOLD (62% confidence). This is not investment advice.
How does MDCXW compare to MD fundamentally?
Medicus Pharma Ltd. has ROE of N/A vs Pediatrix Medical Group, Inc.'s 19.1%. Net margins are 23,954.3% vs 8.6% respectively.
Which stock pays higher dividends, MDCXW or MD?
MDCXW has a dividend yield of N/A or no dividend while MD has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in MDCXW or MD for long term?
For long-term investing, consider that MDCXW has STRONG SELL rating with 95% confidence, while MD has HOLD rating with 62% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about MDCXW vs MD?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For MDCXW vs MD, the AI consensus favors MD based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.